Frontiers in Health InformaticsISSN-Online: 2676-7104 www.healthinformaticsjournal.com
2025; Vol 14: Issue 2 Open Access

Medi Molecule: An AI-Powered Platform for Accelerating Drug Discovery through Molecule Generation and Real-Time Collaboration

Dr. R.M. Noorullah[1*], Dr. Shaik Ruksana Begam[2], Dr. Depruru Shobha Rani[3], Solapuram Shreeya[4]

[1-4]Institute of Aeronautical Engineering, Dundigal, Hyderabad-500043, India.

*Corresponding Author: Dr. R.M. Noorullah, E-mail: noorullah.rm@iare.ac.in

Cite this paper as: Dr. R.M. Noorullah, Dr. Shaik Ruksana Begam, Dr. Depruru Shobha Rani, Solapuram Shreeya (2024), Medi Molecule: An AI-Powered Platform for Accelerating Drug Discovery through Molecule Generation and Real-Time Collaboration. *Frontiers in Health Informatics*, *14(2) 2534-2544*

Abstract: **Introduction**: Medi Molecule is changing drug discovery with its AI platform that tackles common challenges in pharmaceutical research. Traditional drug discovery can take a lot of time and effort, often slowed down by manual data analysis. Using AI models like Nvidia MolMIM, Medi Molecule improves the search, creation, and analysis of molecules. Its strong connections with databases like PubChem and RDKit provide researchers with a wealth of chemical data and solid molecular modeling tools. The platform also features real-time collaboration, allowing researchers to interact and share ideas easily. Interactive data visualizations give useful insights into molecular properties, helping scientists make informed decisions. Medi Molecule is designed for scalability, security, and ease of use, making it an essential tool for scientists, academia, and pharmaceutical companies. This innovative platform shows how AI can help in drug discovery, cutting down time and costs while making it easier to develop life-saving drugs.

Objectives: Molecular Generation**,** Molecular Scoring and Interpretation, and Molecule Representation and Input Handling,

Methods: In the Medi Molecule project, RDKit plays a crucial role in the cheminformatics pipeline. It supports several stages of the machine learning-based drug discovery process. When users enter a SMILES representation of a molecule, RDKit converts it into a molecular graph, where atoms are nodes and bonds are edges. This molecular graph structure is vital for many computational treatments and manipulations, which helps deepen the understanding of molecular structures. Additionally, RDKit allows for the conversion between SMILES and other molecular representations, providing flexibility in how molecules can be represented and how molecular information is input into the system.

Results: Medi Molecule's main features, driven by artificial intelligence tools and real-time collaboration, have greatly improved the drug discovery process. These innovations have brought revolutionary changes that help scientists work faster, one of the platform's most valuable features is its AI-based search function, which has drastically reduced the time needed to access useful molecular information. Combining molecule generation with toxicity prediction models has given researchers initial estimates of the safety profiles for newly identified chemicals.

Conclusions*: The frontend connects to the backend through API endpoints, facilitating the smooth transfer of user inputs like SMILES strings and molecular parameters. For molecule generation, Nvidia MolMIM assists in the backend, while RDKit is responsible for tasks such as molecular visualization, descriptor calculation, and optimization. Furthermore, PubChem APIs confirm that the generated*

compounds are original.

Keywords: Molecular Modeling, Nvidia MolMIM, PubChem, Pharmaceutical Research, Real-Time Communication, RDKit.

INTRODUCTION

Traditionally, finding medications takes time. It is a resource-intensive project that is often complicated by the large amount of data that needs sorting and the challenge of identifying several promising drug candidates. Typically based on trial and error, traditional methods for drug identification involve experiential testing and human data analysis. These factors can increase costs and extend timelines. However, recent advancements in artificial intelligence (AI) and data-driven technologies have begun to change this landscape. AI tools provide a promising way to speed up drug discovery by automating data analysis, optimizing molecular design, and improving collaboration in research.

Medi Molecule stands out with its advanced molecule generation feature, which uses Nvidia's MolMIM model. This state-of-the-art AI model allows the creation of new molecules with specific properties, effectively moving beyond trial-and-error methods. With machine learning, Medi Molecule can accurately predict how molecules will behave, enabling researchers to identify promising drug candidates more quickly. This strategy not only speeds up the drug discovery process but also uncovers molecular characteristics that may have been invisible to traditional methods.

In addition to its AI capabilities, Medi Molecule uses data visualization technologies that let researchers closely examine and assess complex molecules. The platform provides visualizations and interactive maps for users, offering important insights about molecular traits, relationships, and structures. This feature assists scientists in recognizing patterns and connections that might otherwise be missed. By adopting this data-driven approach, scientists can make better-informed decisions as molecular evidence is presented in a clearer and simpler way, allowing them to focus on the most promising pharmaceutical candidates.

RELATED WORK

Over the past few years, improvements in artificial intelligence (AI) have significantly advanced drug research, especially in molecular drug discovery and generation. The combination of AI and pharmaceutical sciences has led to groundbreaking discoveries that have sped up the drug development process, allowing researchers to find new molecular shapes faster than ever before. Deep learning algorithms have enabled the design of new molecular structures with better features, thus lowering the time and costs associated with traditional drug development.

Generative models are essential in computational drug discovery because they allow effective exploration of chemical spaces that traditional methods cannot access. Variational Autoencoders (VAEs), Generative Adversarial Networks (GANs), and Transformer-based models have been used to model molecular properties and synthesizability, generating potential drug molecules. However, challenges related to data quality, model interpretation, and experimental verification persist. AI-supported computational techniques have shown promise in identifying drug-target interactions. These methods have had positive results in uncovering drug-target interactions. Predicting drug-target interactions is a complex task. AI models must consider various biochemical properties and structural dynamics to make reliable predictions. Machine learning models that use chemical and biological datasets can predict binding affinities and improve molecular docking simulations.

Nvidia Molmim

Nvidia’s MolMIM (Molecular Machine Intelligence Model) is an advanced AI platform from Nvidia that focuses on optimizing and designing molecules. It uses machine learning and deep neural networks to create

new molecular structures by predicting how molecules will behave based on certain parameters and goals. This model is particularly useful in drug discovery because it can generate new molecules that may have positive biological effects, such as enhanced efficacy, improved safety, or better pharmacokinetic properties. MolMIM is trained on extensive chemical datasets to grasp how molecular structures interact and their features

OBJECTIVES

Molecular Generation: Nvidia MolMIM creates new molecules from SMILES strings and other parameters, such as the number of molecules, minimum similarity, particles, and iterations. The resulting molecules have desired traits like bioactivity, toxicity, and stability. These molecules can be optimized and screened for drug discovery.

Optimization of Existing Molecules: MolMIM can improve current molecules by recommending structural changes that enhance their effectiveness, making them better candidates for drug development.

High-Performance Computing: With Nvidia's powerful GPUs, MolMIM can perform large-scale simulations and molecular calculations quickly. This significantly cuts down the time needed to generate candidate molecules compared to traditional methods.

Drug Discovery Applications: This model speeds up the drug discovery process by helping researchers identify promising drug molecules more quickly and effectively.

METHODS

Working of the Molecule Generator in Medi Molecule

Medi Molecule, the SMILES to Molecule generator, produces molecular structures using Nvidia MolMIM to meet consumer needs and create molecules tailored for specific requirements. Here's how the process works:

SMILES String: A simplified molecular input line entry, the SMILES string, shows the structure of the molecule.

Number of Molecules: The quantity of molecules to be generated

Minimum Similarity: Similarity assesses how closely the generated molecules match the input system.

Particles: Particles refer to the number of candidates or particles examined during the optimization process.

Iterations: The planned total of iterations through which one can refine the resulting molecules.

MolMIM uses additional data alongside the SMILES string data to generate a set of novel molecules. The AI model considers various factors, including stability, toxicity, and biological activity, which are predictive of these molecular configurations. Users can adjust the number of molecules to explore a larger pool of candidates. The minimum similarity ensures that the new molecules possess several important qualities of the original ones. MolMIM is enhancing the molecule generation process by creating many high-quality molecules.

Molecular Scoring and Interpretation:

After the molecules are created, each one is assessed for suitability and potential in drug development. The score has several purposes:

Score Interpretation: The score acts as a fitness marker to predict how successful or suitable a molecule may be for a specific drug discovery project, based on how well it meets required criteria, such as bioactivity, stability, and toxicity.

Higher Score: Molecules with a higher score often have lower toxicity, greater stability, and higher biological activity.

Lower Score: Molecules with lower scores might require more optimization or may lack necessary biological or chemical features for successful drug development. The score also highlights how effectively the AI model generated the molecular structure under specified conditions and its potential as a pharmaceutical candidate.

PUBCHEM

The National Center for Biotechnology Information (NCBI) and the U.S. National Library of Medicine (NLM) operate PubChem, a free and easy-to-use chemical database. It contains millions of chemical compounds along with extensive details about their properties, structures, biological activities, safety data, and citations in scientific literature. Key features in Medi Molecule's Chemical Structure and Properties include the shown molecular structure, IUPAC nomenclature, molecular weight, solubility, and boiling/melting points.

Bioactivity Data: It provides researchers with information on how compounds interact with biological targets, enabling them to find potential drug candidates.

Toxicology and Safety Data: This gives details on toxicity, hazard ratings, and safety measures related to chemicals in toxicology and safety data.

APIs for Integration: It allows developers to access compound data programmatically through RESTful APIs. Medi Molecule uses PubChem to enhance AI-driven drug discovery by integrating chemical data, structure-focused searches, and biological activity information. Here's how it contributes to different aspects of the project:

Retrieving Chemical Information for AI-Generated Molecules: When Medi Molecule generates a new molecule using Nvidia's MolMIM, it checks if the molecule exists in chemical databases. The system calls PubChem's API to search for similar molecular structures and obtain important properties such as molecular weight, logP (lipophilicity), toxicity, and solubility. If the molecule is not found, Medi Molecule can suggest it as a new drug candidate.

Enhancing AI-Powered Search and Molecular Predictions: Users can input a chemical name, SMILES representation, or molecular formula into Medi Molecule. The platform uses PubChem's structure search API to retrieve similar molecules, which aids in predicting drug actions and interactions. By integrating bioactivity and toxicity data from PubChem, Medi Molecule improves its AI model's ability to rank molecules based on their pharmaceutical potential.

Drug Repurposing and Lead Optimization: Drug repurposing involves finding new uses for existing drugs. Utilizing PubChem's bioactivity data, Medi Molecule can identify existing molecules that can be modified for better therapeutic effects. AI-powered analysis suggests structural changes and compares the new molecules formed with known drugs to evaluate their effectiveness.

RDKit

RDKit is an open-source cheminformatics toolkit commonly used to handle chemical data tasks. This includes manipulating molecular structures, conducting cheminformatics calculations, and visualizing chemical information. Researchers and developers favor it because it supports various activities in computational chemistry, drug discovery, and molecular modeling.

Molecule Representation and Input Handling:

In the Medi Molecule project, RDKit plays a crucial role in the cheminformatics pipeline. It supports several stages of the machine learning-based drug discovery process. When users enter a SMILES representation of a molecule, RDKit converts it into a molecular graph, where atoms are nodes and bonds are edges. This molecular graph structure is vital for many computational treatments and manipulations, which helps deepen the understanding of molecular structures. Additionally, RDKit allows for the conversion between SMILES and other molecular representations, providing flexibility in how molecules can be represented and how molecular information is input into the system.



Figure 1: Distribution of Molecular Properties for Generated Molecules using RDKit

Molecular Descriptor Calculation and Validation:

RDKit is used to find molecular descriptors like molecular weight, hydrophobicity, and polar surface area. These are crucial for assessing a molecule's properties, toxicity, and potential biological activity. These descriptors help evaluate a molecule's suitability as a drug candidate by providing important information on how these molecules behave in biological contexts. RDKit works with MolMIM to conduct similarity searches, comparing new substances with those in databases like PubChem to confirm their uniqueness. This is vital for avoiding duplications of compounds that have already been studied extensively, thereby improving the efficiency of the drug discovery process.

REAL-TIME COLLABORATION IN MEDI MOLECULE:

Medi Molecule encourages real-time collaboration to promote smooth interaction among researchers and scientists involved in drug discovery. Built on cloud technology, this feature allows multiple users to access, edit, and review molecular data at the same time, boosting efficiency and productivity. This collaborative approach lets teams share results, make quicker decisions, and enhance research findings without the delays of asynchronous communication. Researchers can work together on molecular generation, share insights, and update information in real time, which speeds up the drug discovery process, especially for complex tasks like molecular design and analysis. Additionally, role-based access control ensures data security and tailored collaboration among team members. Integrated annotation and chat features improve communication and quicken feedback.

Ably supports Medi Molecule by providing instant and reliable real-time data synchronization for all connected users. This feature enables immediate updates on molecular data, experimental outcomes, and findings using AI, ensuring that all team members have access to the latest information. The functionality offered by Ably is especially important in the fast-paced field of drug discovery, where timely access to updated information is crucial.



Figure 2: Proportional representation of technologies employed in Medi Molecule

Through Ably, the system supports multiple users interacting at the same time without losing performance. It provides a smooth and uninterrupted experience while advancing research. Alby's scalable architecture is essential for Medi Molecule as it efficiently processes large amounts of real-time data exchange and accommodates more users. Its ability to handle frequent updates allows researchers to collaborate in real time, anywhere, without delays or differences in data.

RESULTS

Medi Molecule's main features, driven by artificial intelligence tools and real-time collaboration, have greatly improved the drug discovery process. These innovations have brought revolutionary changes that help scientists work faster.

One of the platform's most valuable features is its AI-based search function, which has drastically reduced the time needed to access useful molecular information. The new technology enables experts to perform sophisticated searches of extensive chemical databases like RDKit and PubChem, delivering faster and more accurate results than previous methods.

The platform sorts and filters huge amounts of information effective by means of complex algorithms. The user-friendly interface of the search tool has been praised for making sophisticated database queries simpler, making it even available to those with minimal computational experience. Such democratization of powerful search facilities further broadens the usefulness of the platform in heterogeneous research environments.

The platform efficiently sorts and filters vast amounts of information using complex algorithms. Users praise the search tool's simple interface for making complex database queries easier, allowing access even for those with limited computational skills. This democratization of powerful searching tools broadens the platform's usefulness in various research environments. The ability to generate molecules, powered by advanced AI algorithms, represents another significant breakthrough in drug discovery. This capability lets scientists create new molecular compounds that meet specific design criteria, such as bioactivity, molecular weight, solubility, and toxicity profiles. Early test results from projects using this feature look very promising, with many

molecular structures showing the desired traits for further study. The Nvidia MolMIM automates molecule generation, while RDKit is used for tasks like molecular visualization, descriptor calculation, and optimization. PubChem APIs check for similarity, ensuring that the generated molecules are unique. The backend processes the results and sends them back to the frontend for users to view and interact with. For real-time synchronization and collaboration, Ably helps users see results and iterate on their investigations instantly. This technology enhances the platform's performance, scalability, and usability, making the drug discovery process more efficient and engaging. By integrating these technologies into a streamlined workflow, Medi Molecule offers a well-organized, data-driven molecular discovery process that allows exploration of more design possibilities. Medi Molecule not only speeds up the discovery of potential drug candidates but also reduces the trial-and-error aspect of manual molecular design. Scientists can now design more compounds in fewer hours, increasing the chances of finding a functional drug candidate. Automating experiments also improves reproducibility, delivering reliable and consistent results that can scale for industrial production.

Additionally, combining molecule generation with toxicity prediction models has given researchers initial estimates of the safety profiles for newly identified chemicals. This built-in evaluation feature allows researchers to rule out toxic candidates early in the drug discovery process, saving time and effort. Future improvements, including merging deep learning models with larger training datasets, will further enhance its accuracy and make it applicable to more advanced molecular designs. This series of gradual improvements promises to make Medi Molecule a crucial tool in the pharmaceutical industry's quest for breakthrough treatments.

Through Ably's real-time collaboration, synchronized data changes enable distributed teams to work effectively without version conflicts. Meanwhile, the backend system efficiently processes complex calculations and retrieves large data from RDKit and PubChem APIs.

Data visualization is another key aspect of Medi Molecule's offerings. It allows researchers to present complex chemical and biological data in easy-to-understand ways. Interactive visualizations within the platform facilitate faster and clearer interpretation of experimental data. Features such as 3D molecular modeling, heatmaps, and dynamic charts enhance the understanding of complex datasets.



Figure 3: Visualization of AI Parameters in Medi Molecule for Drug Discovery Optimization

These visualizations have been emphasized by researchers to clarify their findings and improve communication among interdisciplinary teams. Biologists and chemists working together on a project may use the site to share graphical representations of their data. This helps connect the two fields and supports collaborative problem-solving.

Additionally, the ability to customize visualizations for each project allows researchers to tailor their analysis to specific issues and goals. For example, biologists and chemists can use the website to share data visualizations, bridging the gap between their fields. The option to adjust visualizations based on a project's needs ensures that researchers can conduct analyses suited to their unique problems.

DISCUSSION

In particular, the real-time collaboration feature of the platform has transformed the way research is conducted, especially in remote settings. By quickly sharing experimental results, notes, and datasets, Medi Molecule has significantly cut down the time needed for decision-making. Researchers can now communicate instantly, give feedback, and make joint decisions without relying on lengthy email threads or in-person meetings.

This has proven especially beneficial during the COVID-19 pandemic. The platform's secure data-sharing policies and access restrictions help keep sensitive information safe, fostering trust within teams. Moreover, teams can track changes to data sets through version control features and, if necessary, revert to older versions, further boosting the reliability of group efforts.

Looking ahead, there are opportunities for Medi Molecule to grow even more. One way is to develop better AI algorithms to improve the accuracy and variety of molecule generation. By using advanced machine learning techniques and adding larger training sets, the platform could enable the creation of more complex and biologically active molecules. This would be particularly valuable for treating intricate diseases that require specific therapeutic agents.

Furthermore, adding pharmacokinetic and pharmacodynamic modeling software would help researchers understand how potential drug candidates interact with biological systems. This comprehensive view would streamline the transition from early discovery to preclinical testing, shortening the overall drug development timeline.

Another important area for improvement is the platform's scalability and performance optimization. As research teams grow and their projects become more complex, Medi Molecule needs to handle larger data sets and more demanding queries without losing performance.

Table 1: Sample Molecular Structures before and after SMILES String preprocessing

Mole cule ID	Raw SMILES String	Preprocessed SMILES String	Molecular Weight
101	CC(=O) Oc1ccccc 1C(=O) O	CCOc1ccccc 1C(=O) O	180.16
102	C1=CC=C(C=C1) C=O	C1=CC=C (C =C1) C=O	106.12
103	O=C(C)Oc1ccccc 1C(=O) O	OC(=O) c1cc ccc1C(=O) O	210.18

Improvements to the platform's infrastructure, like using cloud-based technologies and parallel processing methods, would help keep it responsive and efficient even with heavy workloads.

Additionally, creating modular components that can be customized for individual users or research groups would further enhance the platform's flexibility and usability. Increasing the platform's integration with external databases and tools presents another great opportunity. By combining Medi Molecule with resources such as clinical trial registries, genomic databases, and cheminformatics tools, scientists could access valuable streams of additional information to support their work.



Figure 4: Molecule generation process in Medi Molecule, demonstrating the input parameters (SMILES string, similarity, particle count, and iterations) and the generated chemical structures with their respective scores.

CONCLUSION

The use of artificial intelligence methods in drug discovery represents a significant change in the pharmaceutical industry. It alters how scientists approach medication development. With generative artificial intelligence, real-time data integration, and predictive analysis, Medi Molecule significantly speeds up identification. This reduces market timing and improves research efficiency. The platform can automate complex molecular design processes, which allows scientists to focus on higher-level decisions, strategic planning, and hypothesis testing. Additionally, the collaborative features within Medi Molecule promote smooth teamwork, especially for research groups in different locations. This feature cuts down communication delays and supports understanding. It also improves workflow integration, ensuring effective communication between various modules. This leads to productive creation, analysis, and validation of molecules. The frontend connects to the backend through API endpoints, facilitating the smooth transfer of user inputs like SMILES strings and molecular parameters. For molecule generation, Nvidia MolMIM assists in the backend, while RDKit is responsible for tasks such as molecular visualization, descriptor calculation, and optimization. Furthermore, PubChem APIs confirm that the generated compounds are original. The backend processes this information and sends the results to the frontend for user interaction and visualization. Ably enables real-time updates, helping users view results and quickly adjust their research. This organized integration enhances scalability, performance, and usability, making the drug discovery process more engaging and effective.

By integrating these technologies into a smooth workflow, Medi Molecule offers an efficient, data-driven strategy for molecular discovery. This approach encourages innovation and accelerates research achievements. In the future, Medi Molecule could become a powerful, all-purpose tool. By improving its AI algorithms with advanced deep learning techniques, it may generate compounds with even greater precision. Moreover, designing a more intuitive and user-friendly UI would make it more accessible to researchers. Incorporating other datasets, such as pharmacokinetic and pharmacodynamic data, could provide a more comprehensive drug discovery strategy. By overcoming current limitations and expanding its features, Medi Molecule is well-positioned to become a highly scalable platform. These improvements would not only speed up drug discovery but also enhance understanding of molecular interactions, bioactivity predictions, and therapeutic effectiveness. Ultimately, this would establish Medi Molecule as a foundation for modern pharmaceutical research, driving innovation and advancing the development of lifesaving medications.

FUTURE WORK

The integration of AI-driven molecular generation and cheminformatics software, including Nvidia MolMIM and RDKit, has opened new avenues for innovation in drug discovery. While Medi Molecule lays a strong foundation for AI-enhanced drug discovery, several potential upgrades could further boost its efficiency and relevance.

Enhanced Molecular Optimization Future versions of Medi Molecule could utilize reinforcement learning and generative models to optimize molecules in real time. By incorporating feedback from docking simulations and bioactivity assessments, the platform could evolve to create more effective drug candidates with fewer side effects.

Incorporation of Experimental Data Currently, Medi Molecule relies mainly on computational methods. Future developments could involve integrating experimental data from wet labs to validate molecules predicted by AI. This combined approach would blend AI-generated predictions with actual lab outcomes

Broadening Chemical Data Repositories While PubChem serves as a key resource for checking molecular similarity, adding databases like ChEMBL, Drug Bank, and PDB (Protein Data Bank) will enhance the verification and validation processes. A larger dataset will allow for better evaluation of novelty and improve lead discovery.

Real-Time Cloud-Enabled Deployment Deploying Medi Molecule on the cloud would enable worldwide access to the platform. By utilizing serverless computing, containerization (Docker), and cloud-based GPUs, researchers could achieve real-time AI-assisted drug discovery at scale.

Enhanced Explainability with AI Interpretation Techniques To foster trust and usability, incorporating explainable AI (XAI) techniques will help researchers understand the reasoning behind the generation and selection of specific molecules. Techniques like SHAP and attention mechanisms in deep learning models can provide clarity on molecular predictions.

Advanced 2D/3D Visualization for Molecular Evaluation Future improvements might focus on enhancing molecular visualization with interactive 2D and 3D tools. These upgrades would allow researchers to manipulate structures in real time, analyze functional groups, and effectively simulate potential biological interactions,

API and Plugin Development for the Research Community to expand Medi Molecule's reach, APIs and plugins for popular computational chemistry tools like PyMOL, AutoDock, and Open Babel could be created. This would facilitate seamless integration with existing workflows used by researchers in academia and industry.

ACKNOWLEDGEMENTS

This study was conducted without any external financial support. The authors confirm that there are no conflicts of interest. They also thank all reviewers for their valuable feedback, which has helped to improve this work.

REFRENCES

1. Bagal V, et al. (2022). MolGPT: molecular generation using a transformer-decoder model, DOI: 10.1021/acs.jcim.1c00600.
2. Du Y, et al. (2024). Machine learning-aided generative molecular design, DOI: 10.1038/s42256-024-00843- 5.
3. Huanbutta K, et al. (2024). Artificial intelligence- driven pharmaceutical industry: A paradigm shifts in drug discovery, formulation development, manufacturing, quality control, and post-market surveillance, DOI: 10.1016/j.ejps.2024.106938.

4. Leguy J, et al. (2020). Goal-directed generation of new molecules by AI methods. In: Advances in Artificial Intelligence and Data Engineering, Elsevier, pp. 53–71.doi.org/10.1016/B978-0-12- 822249-2.00004-9.
5. Ma B, Terayama K, et al. (2021). Structure- based de novo molecular generator combined with artificial intelligence and docking simulations, DOI: 10.1021/acs.jcim.1c00679.
6. Mock M, et al. (2024). Recent advances in generative biology for biotherapeutic discovery. Trends in Pharmacological Sciences, DOI: 10.1016/j.tips.2024.01.003.
7. Mouchlis VD, et al. (2021). Advancing computational drug discovery with artificial intelligence, DOI: 10.3390/ijms22041676.
8. Nigam A, et al. (2020). Augmenting genetic algorithms with deep neural networks for exploring the chemical space. *Nature Machine Intelligence*, DOI:10.48550/arXiv.1909.11655.
9. Paul D, et al. (2020) Artificial intelligence in drug discovery and development, DOI: 10.1016/j.drudis.2020.10.010.
10. Ren F, et al. (2024). AlphaFold accelerates artificial intelligence- powered drug discovery: efficient discovery of a novel CDK20 small molecule inhibitor. Chemical Science, DOI: 10.1039/d2sc05709c.
11. Visan Anita Ioana and Negut Irina. (2024). Integrating artificial intelligence for drug discovery in the context of revolutionizing drug delivery, DOI: 10.3390/life14020233.
12. Yadav S, et al. (2024). Revolutionizing drug discovery: The impact of artificial intelligence on advancements in pharmacology and the pharmaceutical industry, DOI: 10.1016/j.ipha.2024.02.009.
13. Yugo Shimizu, et al. (2023). AI-driven molecular generation of not-patented pharmaceutical compounds using world open patent data, DOI: 10.1186/s13321-023-00791-z.
14. Zeng X, et al. (2022). Deep generative molecular design reshapes drug discovery. *Xenotransplantation and Cellular Medicine*, DOI: 10.1016/j.xcrm.2022.100794.